Kiniksa Pharmaceuticals, Ltd. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed February 25, 2021. This is an annual filing, not a standalone Q4 report. Kiniksa is a Bermuda-incorporated, clinical-stage biopharmaceutical company (Nasdaq: KNSA) focused on immunology and inflammatory-disease therapies. It reported no product revenue.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $112.0 million | $135.0 million |
| Selling, general and administrative expense | $45.3 million | $35.0 million |
| Total operating expenses / operating loss | $157.4 million | $170.0 million |
| Net loss | $161.4 million | $161.9 million |
| Basic and diluted loss per share | $2.61 | $2.99 |
| Net cash used in operating activities | $136.5 million | $158.4 million |
- At year-end, cash, cash equivalents and short-term investments were $323.5 million; working capital was $301.4 million. Current assets were $333.2 million and current liabilities $31.8 million.
- Total liabilities were $37.5 million, principally accrued expenses and operating lease obligations. The filing does not report interest-bearing debt; operating lease liabilities were $7.0 million.
- Financing activities provided $227.1 million in cash, including $220.5 million net proceeds from two 2020 share offerings and private placements. Cash, cash equivalents and restricted cash increased $67.1 million.
- Accumulated deficit was $517.5 million. Profit margins are not meaningful because the company had no product revenue and incurred operating losses.
- Management expected existing cash and investments to fund operating and capital needs for at least 12 months from issuance of the financial statements, while noting that additional financing would be needed to fund operations beyond that period.
Material changes and business developments
- Rilonacept: The pivotal Phase 3 RHAPSODY trial in recurrent pericarditis met its primary and major secondary endpoints. The filing reports a 96% lower recurrence risk versus placebo (hazard ratio 0.04; p<0.0001). The FDA accepted the supplemental BLA for priority review, with a March 21, 2021 PDUFA goal date. Kiniksa anticipated a possible U.S. launch in the first half of 2021 if approved.
- Mavrilimumab: A Phase 2 giant cell arteritis trial met its primary and secondary endpoints; flare risk was lower versus placebo (hazard ratio 0.38; p=0.0263), and Week 26 sustained remission was 83.2% versus 49.9%. A Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation was ongoing.
- Vixarelimab: The Phase 2a prurigo nodularis trial met its primary endpoint; the company began a Phase 2b dose-ranging study.
- KPL-404: Preliminary Phase 1 results showed full receptor occupancy and complete suppression of the test-antigen antibody response through Day 29 in the six subjects receiving 3 mg/kg intravenously, with no dose-limiting safety findings reported at that stage.
Compared with 2019, net loss was nearly flat despite lower total operating expenses. R&D fell 17%, partly reflecting the absence of the prior-year $18.0 million Primatope acquisition-related charge and $10.0 million Biogen milestone, while 2020 included a $7.5 million Regeneron regulatory milestone and higher mavrilimumab program spending. SG&A rose 30%, mainly due to personnel and rilonacept pre-commercialization costs. Interest income declined to $1.1 million from $6.0 million, largely because of lower interest rates. Loss per share narrowed, with weighted-average shares increasing to 61.8 million from 54.0 million.
Outlook, risks and contingencies
- No numerical revenue, earnings or cash-flow guidance was provided. Management described expected development and commercialization spending as substantial and said losses and operating cash use were expected to continue.
- Rilonacept approval and launch were not assured. Under the Regeneron agreement, Kiniksa would assume U.S. sales and distribution for approved indications and share profits with Regeneron after specified commercialization expenses. A further $20.0 million regulatory milestone could be due in Q1 2021 if its specified condition was met.
- Key risks include clinical and regulatory uncertainty, COVID-19-related trial and operating disruption, reliance on third-party manufacturers and CROs, potential supply constraints, market access and reimbursement, competition, and the need for additional capital. Rilonacept supply is dependent on Regeneron and its manufacturing arrangements.
- Contractual commitments included $16.2 million of manufacturing commitments due in 2021 and $7.5 million of operating lease payments. Additional license milestones and royalties are contingent; amounts and timing depend on future achievements and sales.
- The company recorded a $5.2 million income tax provision in 2020, primarily reflecting a valuation allowance and current tax expense. It reported no material legal proceedings. The independent auditor issued an unqualified opinion and reported effective internal control over financial reporting.
- After year-end, in January 2021, Kiniksa transferred rilonacept-related rights and assets to its U.K. subsidiary as part of launch readiness. The filing also said a senior operations and commercial officer departed in January 2021.
Most important facts for investors to verify
- The FDA’s decision and any label, timing or conditions for rilonacept in recurrent pericarditis, including the associated milestone and profit-sharing terms.
- Updated cash burn, operating costs and capital needs against the stated cash runway, as well as any further equity issuance or dilution.
- Final and subsequent clinical data, safety findings and development plans for mavrilimumab, vixarelimab and KPL-404.
- Manufacturing readiness, supply continuity, reimbursement and early commercial uptake if rilonacept is approved.
- Progress against contingent licensing milestones and the financial implications of royalty, profit-share and other collaboration agreements.